Results 31 to 40 of about 23,963 (194)

Fingolimod: therapeutic mechanisms and ocular adverse effects. [PDF]

, 2017
Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). We aim to review the published literature on ocular manifestations of fingolimod therapy and their possible underlying mechanisms.
A Groves, A Gupta, A Minuk, A Schwarz, AR Afshar, B Nealon, BJ McVerry, C Aguiar, D Ontaneda, G Saab, H Chen, H Tedesco-Silva, J Camm, J Chui, J Chun, JA Cohen, JA Cohen, JM Gelfand, K Schroder, K Turaka, L Kappos, L Kappos, L Liu, M Brar, M Salvadori, MA Zarbin, ML Oo, MT Bhatti, N Ueda, OJ Coppes, P A Keane, P Mandal, PA Calabresi, R Gallego-Pinazo, R Moosavi, RS Brush, S Thoo, V Li, VM Asensio-Sanchez, W Fusi-Rubiano, Y Yang   +40 more
core   +1 more source

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series

BMC Neurology, 2021
Background Fingolimod is a S1P1 receptor modulator that prevents activated lymphocyte egress from lymphoid tissues causing lymphopenia, mainly affecting CD4+ T lymphocytes.
Silvia Delgado, Jeffrey Hernandez, Leticia Tornes, Kottil Rammohan   +3 more
doaj   +1 more source

Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study [PDF]

, 2017
Background First dose observation for cardiac effects is required for fingolimod, but recommendations on the extent vary. This study aims to assess cardiac safety of fingolimod first dose.
Dechend, Ralf, Haverkamp, Wilhelm [u. v. a.], Limmroth, Volker   +2 more
core   +1 more source

Fingolimod for the treatment of neurological diseases—state of play and future perspectives [PDF]

, 2014
Sphingolipids are a fascinating class of signaling molecules derived from the membrane lipid sphingomyelin. They show abundant expression in the brain.
Rajkumar Vutukuri, Robert Brunkhorst, Waltraud Pfeilschifter   +2 more
core   +2 more sources

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis

Frontiers in Neuroscience, 2017
Objective: It is well-known that initiation of fingolimod induces a transient decrease of heart rate. However, the underlying cardiac autonomic regulation is poorly understood. We aimed to investigate the changes of autonomic activity caused by the first
Kai Li, Kai Li, Urszula Konofalska, Katja Akgün, Manja Reimann, Heinz Rüdiger, Rocco Haase, Tjalf Ziemssen, Tjalf Ziemssen   +8 more
doaj   +1 more source

Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing. [PDF]

PLoS ONE, 2015
In multiple sclerosis (MS) patients, Fingolimod may induce prolonged heart-rate slowing which might be caused by MS-related central autonomic lesions.To evaluate whether MS-patients with prolonged heart-rate slowing (> six hours) upon Fingolimod show ...
Max J Hilz, Tassanai Intravooth, Sebastian Moeller, Ruihao Wang, De-Hyung Lee, Julia Koehn, Ralf A Linker   +6 more
doaj   +1 more source

Relapsing-remitting multiple sclerosis: advances in disease-modifying therapies [PDF]

, 2015
Multiple sclerosis is a demyelinating disease affecting the central nervous system. It is the most prevalent disabling neurological condition among young adults, with onset typically between 20 and 40 years of age. Infiltrating immune cells and microglia
Kay, Kathleen Alexandra
core   +1 more source

Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund, Johan Reutfors, Thomas Frisell, Fredrik Piehl   +3 more
wiley   +1 more source

Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis

Journal of Ophthalmic Inflammation and Infection, 2020
Background Patients with multiple sclerosis (MS) have a higher incidence of uveitis compared with the general population. Fingolimod, a first line disease modifying drug used in multiple sclerosis, may cause macular edema and thus requires ophthalmic ...
Scott Joseph Sonne, Bradley Thomas Smith
doaj   +1 more source

Safety monitoring of the newer disease modifying therapies in multiple sclerosis patients in Mater Dei hospital [PDF]

, 2016
Patients with highly active Multiple Sclerosis can be started on the newer pharmaceutical agents, Dimethyl Fumarate or Fingolimod. Safety monitoring recommended includes regular blood analysis and also ophthalmic tests and MRI scans in the case of ...
Aquilina, Josanne, Zammit, Daniela
core